ArticlePharmacoEconomics2015
Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment.
Article in PharmacoEconomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Willingness to Pay per QALY: A Systematic Review of Demand-Side Valuations with a Focus on Age and Disease Severity.Applied health economics and health policy · 2026Pooled it
- Systematic Review of the Relative Social Value of Child and Adult Health.PharmacoEconomics · 2024Pooled it
- Pooled it
- Current Practices for Accounting for Preference Heterogeneity in Health-Related Discrete Choice Experiments: A Systematic Review.PharmacoEconomics · 2022Pooled it
- Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression.The European journal of health economics : HEPAC : health economics in prevention and care · 2022Pooled it
- Discrete Choice Experiments in Health Economics: Past, Present and Future.PharmacoEconomics · 2019Pooled it
- Using Latent Class Analysis to Model Preference Heterogeneity in Health: A Systematic Review.PharmacoEconomics · 2018Pooled it
- Does the Public Prefer Health Gain for Cancer Patients? A Systematic Review of Public Views on Cancer and its Characteristics.PharmacoEconomics · 2017Pooled it
- Towards meaningful outcome measures for health economic evaluations in skin cancer : A decision matrix to guide transparent outcome selection in skin cancer health economic evaluations, supporting more informed decision-making.Cost effectiveness and resource allocation : C/E · 2026Article
- The value of health and well-being from a societal perspective: A willingness to pay experiment in the Netherlands.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Article
- Examining the Effect of Depicting a Patient Affected by a Negative Reimbursement Decision in Healthcare on Public Disagreement with the Decision.PharmacoEconomics · 2024Article
- What Aspects of Illness Influence Public Preferences for Healthcare Priority Setting? A Discrete Choice Experiment in the UK.PharmacoEconomics · 2021Article
- How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.Frontiers in pharmacology · 2021Review
- Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries.Frontiers in pharmacology · 2021Review
- Article
- Value judgment of new medical treatments: Societal and patient perspectives to inform priority setting in The Netherlands.PloS one · 2020Article
- When is it too expensive? Cost-effectiveness thresholds and health care decision-making.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Article
- Using discrete choice model to elicit preference for health-care priority setting.Journal of education and health promotion · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo judge whether an intervention offers value for money, the incremental costs per gained quality-adjusted life-year (QALY) need to be compared with some relevant threshold, which ideally reflects the monetary value of health gains. Literature suggests that this value may depend on the equity context in which health gains are produced, but the value of a QALY in relation to equity considerations has remained largely unexplored.
objectiveThe objective of this study was to estimate the social marginal willingness to pay (MWTP) for QALY gains in different equity subgroups, using a discrete choice experiment (DCE). Both severity of illness (operationalized as proportional shortfall) and fair innings (operationalized as age) were considered as grounds for differentiating the value of health gains.
methodsWe obtained a sample of 1205 respondents, representative of the adult population of the Netherlands. The data was analysed using panel mixed multinomial logit (MMNL) and latent class models.
resultsThe panel MMNL models showed counterintuitive results, with more severe health states reducing the probability of receiving treatment. The latent class models revealed distinct preference patterns in the data. MWTP per QALY was sensitive to severity of disease among a substantial proportion of the public, but not to the age of care recipients.
conclusionThese findings emphasize the importance of accounting for preference heterogeneity among the public on value-laden issues such as prioritizing health care, both in research and decision making. This study emphasises the need to further explore the monetary value of a QALY in relation to equity considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.